J&J gets FDA breakthrough therapy status for nipocalimab in Sjogren’s
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
Iryna Drozd
- Johnson & Johnson (NYSE:JNJ) has received FDA breakthrough therapy designation for its drug candidate nipocalimab in the treatment of moderate-to-severe Sjogren’s disease.
- The FDA also granted breakthrough therapy designation to nipocalimab earlier this year for hemolytic disease of the fetus and newborn, according to a statement.